Changes in BDNF expression after different types of brain insults are related to neuroprotection, stimulation of sprouting, and synaptic reorganization. In the cerebral cortex, an autocrine-paracrine mechanism for BDNF has been proposed because the distribution patterns of BDNF and TrkB expression are almost identical. Moreover, cortical BDNF is anterogradely transported to the striatum, suggesting a role of BDNF in the functional interaction between the two brain regions. Here we have examined the expression of this neurotrophin in the cerebral cortex after various striatal lesions. Intrastriatal injection of quinolinate, kainate, 3-nitropropionic acid, or colchicine increased BDNF mRNA levels in cerebral cortex. In contrast, stimulation of neuronal activity in the striatum did not change cortical BDNF expression. Both excitatory amino acids increased BDNF expression in neurons of cortical layers II/III, V, and VI that project to the striatum. Moreover, grafting a BDNFsecreting cell line prevented both the loss of striatal neurons and the cortical upregulation of BDNF induced by excitotoxins. Because retrograde transport in the corticostriatal pathway was intact after striatal lesions, our results suggest that striatal damage upregulates endogenous BDNF in corticostriatal neurons by a transneuronal mechanism, which may constitute a protective mechanism for striatal and/or cortical cells.

No abstract

No abstract

No abstract

Bone morphogenetic proteins are members of the transforming growth factor-b superfamily that have multiple functions in the developing nervous system. One of them, bone morphogenetic protein-2 (BMP-2), promotes the differentiation of cultured striatal neurones, enhancing dendrite growth and calbindin-positive phenotype. Bone morphogenetic proteins have been implicated in cooperative interactions with other neurotrophic factors. Here we examined whether the effects of BMP-2 on cultured striatal neurones are mediated or enhanced by other neurotrophic factors. BMP-2 had a cooperative effect with low doses of brain-derived neurotrophic factor or neurotrophin-3 (but not with other neurotrophic factors such as glial cell line-derived neurotrophic factor, neurturin or transforming growth factor-b2) on the number of calbindin-positive striatal neurones. Moreover, BMP-2 induced phosphorylated Trk immunoreactivity in cultured striatal neurones, suggesting that neurotrophins are involved in BMP-2 neurotrophic effects. The addition of TrkB-IgG or antibodies against brain-derived neurotrophic factor abolished the effects of BMP-2 on the number and degree of differentiation of calbindin-positive striatal neurones. Indeed, BMP-2 treatment increased brain-derived neurotrophic factor protein levels in treated cultures media and BDNF immunocytochemistry revealed that this neurotrophin was produced by neuronal cells. Taken together, these results indicate that brain-derived neurotrophic factor mediates the effects of BMP-2 on striatal neurones.

No abstract

No abstract

The maturation of striatal projection neurons and interneurons is influenced by the development and integrity of their connectivity. In the present work, we have analyzed the modulation of striatum vulnerability to quinolinate (QUIN)-induced excitotoxicity in different neuronal populations by the nigrostriatal dopaminergic pathway during postnatal development. A single striatal lesion with 6-hydroxydopamine (6-OHDA) at the second postnatal day (P) 2 or QUIN at P7 induced a reduction in the striatal volume at P30, whereas an additive effect was observed when these two lesions were performed in the same animal. The analysis of different striatal neuronal populations showed that the excitotoxic lesion induced by QUIN over projection neurons stained with calbindin was partially reverted by the previous injection of 6-OHDA at P2. However, cholinergic interneurons were affected neither by the lack of dopamine innervation nor by QUIN treatment. This neuronal population also remained intact after the double lesion. In contrast, the number of other type of striatal interneurons, parvalbumin-positive neurons, were reduced by the dopaminergic ablation and also by the QUIN-induced excitotoxicity and this effect was additive after the double lesion when it was measured at P30. On the other hand, we studied the effect on the striatal outputs measuring the density of substance P-positive fibers in the substantia nigra and enkephalin-positive fibers in the globus pallidus. A reduction in substance P-positive fibers was observed in 6-OHDA injected animals, while the density of enkephalin-positive fibers was only decreased after QUIN treatment. The double lesion did not modify the effects of the single lesions. In conclusion, our results show that dopamine modulates the vulnerability to excitotoxicity during striatal postnatal development, and this effect is specific for projection neurons. Furthermore, striatonigral and striatopallidal pathways are differentially regulated by the activation of dopamine or glutamate receptors.